Revenue is projected to rise between 3.6% and 9% year-on-year, but EBITDA margins are expected to narrow, primarily due to reduced contributions from the US segment. Analysts anticipate flat to slightly positive profit after tax (PAT) growth, with a few even forecasting a decline. Investors will be closely watching the performance of the US business, pricing dynamics of key products, and the recovery momentum in India’s trade generics segment.
Comments
Post a Comment